Antibody persistence against diphtheria, tetanus, pertussis, hepatitis B, measles, mumps and rubella in 5-8-year-old Thai children following primary and first booster immunization with pentavalent vs. hexavalent vaccines
Phase 4
Recruiting
- Conditions
- Vaccine immunogenicitydiphtheria toxoid, tetanus toxoid, aellular pertussis , whole-cell pertussis, mealses, mumps, rubella, hepatitis B. children
- Registration Number
- TCTR20231017001
- Lead Sponsor
- ational Reserach Council of Thailand (NRCT)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Health children who were enrolled in the original trial (ClinicalTrials.gov NCT02408926, TCTR20180926001 ) and received four doses of either DTaP-IPV-HB-Hib or DTwP-HB-Hib + bOPV as primary series and first booster vaccination, and Tdap-IPV as second booster vaccination at the age of four years.
Exclusion Criteria
1. Immunocompromised status
2. Bleeding tendency
3. Parent refusal to participate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Immunogenicity 8 years antibody levels to diphtheria, tetanus, pertussis
- Secondary Outcome Measures
Name Time Method Immunogenicity 8 years Antibody levels to measles, mumps, rubella and hepatitis B